

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

Recombinant Anti-Integrin alpha 2 antibody [EPR5788]

RRID:AB_2833020

Type: Antibody

Proper Citation

Abcam Cat# ab133557, RRID:AB_2833020

Antibody Information

URL: http://antibodyregistry.org/AB_2833020

Proper Citation: Abcam Cat# ab133557, RRID:AB_2833020

Target Antigen: Integrin alpha 2

Host Organism: rabbit

Clonality: recombinant

Comments: Applications: Flow Cyt, WB, IHC-P

Antibody Name: Recombinant Anti-Integrin alpha 2 antibody [EPR5788]

Description: This recombinant targets Integrin alpha 2

Target Organism: mouse, human

Clone ID: EPR5788

Antibody ID: AB_2833020

Vendor: Abcam

Catalog Number: ab133557

Record Creation Time: 20231110T032401+0000

Record Last Update: 20260828T234734+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-Integrin alpha 2 antibody [EPR5788].

No alerts have been found for Recombinant Anti-Integrin alpha 2 antibody [EPR5788].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Eissa IR, et al. (2026) The CD49b (ITGA2) collagen receptor excludes CD8+ T cell infiltration in pancreatic ductal adenocarcinoma. *iScience*, 29(7), 116500.

Zaher DM, et al. (2025) Identifying the Impact of RelA Overexpression in Triple-Negative Breast Cancer Cells Using Mass Spectroscopy-based Proteomics and Metabolomics Analysis. *Chemistry & biodiversity*, e00717.

Deng T, et al. (2025) CINTER-seq: Chemical profiling reveals interaction-dependent cell landscapes and gene signatures in vivo. *Immunity*, 58(9), 2336.

Chen Y, et al. (2022) Oncogenic collagen I homotrimers from cancer cells bind to $\alpha 1$ integrin and impact tumor microbiome and immunity to promote pancreatic cancer. *Cancer cell*, 40(8), 818.

Hu HT, et al. (2021) Ultracentrifugal separation, characterization, and functional study of extracellular vesicles derived from serum-free cell culture. *STAR protocols*, 2(3), 100625.

Oggero S, et al. (2021) Extracellular vesicles from monocyte/platelet aggregates modulate human atherosclerotic plaque reactivity. *Journal of extracellular vesicles*, 10(6), 12084.

Nishimura T, et al. (2021) Filopodium-derived vesicles produced by MIM enhance the migration of recipient cells. *Developmental cell*, 56(6), 842.